Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.44)
# 316
Out of 5,240 analysts
89
Total ratings
55.95%
Success rate
19.98%
Average return
Main Sectors:
Stocks Rated by Srikripa Devarakonda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $640 → $709 | $536.76 | +32.09% | 3 | May 13, 2026 | |
| MBX MBX Biosciences | Maintains: Buy | $50 → $70 | $37.18 | +88.27% | 2 | May 11, 2026 | |
| VTRS Viatris | Maintains: Buy | $18 → $20 | $17.18 | +16.45% | 2 | May 8, 2026 | |
| ABSI Absci | Maintains: Buy | $9 → $11 | $5.56 | +97.84% | 1 | May 8, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $110 → $121 | $104.62 | +15.66% | 5 | Apr 15, 2026 | |
| BIIB Biogen | Maintains: Hold | $193 → $189 | $194.00 | -2.58% | 7 | Apr 13, 2026 | |
| IVA Inventiva | Initiates: Buy | $13 | $5.59 | +132.56% | 1 | Mar 19, 2026 | |
| SEPN Septerna | Maintains: Buy | $34 → $35 | $25.30 | +38.34% | 2 | Mar 11, 2026 | |
| SRRK Scholar Rock Holding | Maintains: Buy | $44 → $55 | $49.80 | +10.44% | 6 | Mar 4, 2026 | |
| CYTK Cytokinetics | Maintains: Buy | $84 → $92 | $77.96 | +18.01% | 5 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $116 | $84.90 | +36.63% | 6 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $79 → $93 | $98.01 | -5.11% | 12 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $940 → $812 | $721.04 | +12.62% | 8 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $21 → $11 | $9.47 | +16.16% | 1 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $10.50 | +138.10% | 5 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,029 → $1,038 | $1,001.83 | +3.61% | 4 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $211 → $217 | $212.45 | +2.14% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $32 | $25.78 | +24.13% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $33.21 | +50.56% | 6 | Nov 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $54 | $1.48 | +3,548.65% | 1 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $4.86 | +208.64% | 7 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $16.07 | +124.09% | 1 | Jul 31, 2024 |
Madrigal Pharmaceuticals
May 13, 2026
Maintains: Buy
Price Target: $640 → $709
Current: $536.76
Upside: +32.09%
MBX Biosciences
May 11, 2026
Maintains: Buy
Price Target: $50 → $70
Current: $37.18
Upside: +88.27%
Viatris
May 8, 2026
Maintains: Buy
Price Target: $18 → $20
Current: $17.18
Upside: +16.45%
Absci
May 8, 2026
Maintains: Buy
Price Target: $9 → $11
Current: $5.56
Upside: +97.84%
Protagonist Therapeutics
Apr 15, 2026
Maintains: Buy
Price Target: $110 → $121
Current: $104.62
Upside: +15.66%
Biogen
Apr 13, 2026
Maintains: Hold
Price Target: $193 → $189
Current: $194.00
Upside: -2.58%
Inventiva
Mar 19, 2026
Initiates: Buy
Price Target: $13
Current: $5.59
Upside: +132.56%
Septerna
Mar 11, 2026
Maintains: Buy
Price Target: $34 → $35
Current: $25.30
Upside: +38.34%
Scholar Rock Holding
Mar 4, 2026
Maintains: Buy
Price Target: $44 → $55
Current: $49.80
Upside: +10.44%
Cytokinetics
Feb 3, 2026
Maintains: Buy
Price Target: $84 → $92
Current: $77.96
Upside: +18.01%
Dec 9, 2025
Maintains: Buy
Price Target: $80 → $116
Current: $84.90
Upside: +36.63%
Oct 29, 2025
Reiterates: Hold
Price Target: $79 → $93
Current: $98.01
Upside: -5.11%
Aug 11, 2025
Maintains: Buy
Price Target: $940 → $812
Current: $721.04
Upside: +12.62%
May 5, 2025
Downgrades: Hold
Price Target: $21 → $11
Current: $9.47
Upside: +16.16%
Apr 9, 2025
Maintains: Buy
Price Target: $43 → $25
Current: $10.50
Upside: +138.10%
Feb 3, 2025
Maintains: Buy
Price Target: $1,029 → $1,038
Current: $1,001.83
Upside: +3.61%
Feb 3, 2025
Maintains: Buy
Price Target: $211 → $217
Current: $212.45
Upside: +2.14%
Dec 18, 2024
Maintains: Buy
Price Target: $36 → $32
Current: $25.78
Upside: +24.13%
Nov 27, 2024
Maintains: Buy
Price Target: $33 → $50
Current: $33.21
Upside: +50.56%
Sep 27, 2024
Upgrades: Buy
Price Target: $54
Current: $1.48
Upside: +3,548.65%
Aug 13, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $4.86
Upside: +208.64%
Jul 31, 2024
Initiates: Buy
Price Target: $36
Current: $16.07
Upside: +124.09%